We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 16 OCTOBER 2012
Federal Circuit Clarifies Obviousness-Type Double Patenting Between Products And Methods
Foley & Lardner LLP
In "Eli Lilly and Company v. Teva Parenteral Medicines, Inc"., the Federal Circuit affirmed the district court’s decision that Eli Lilly’s patent to pemetrexed is not invalid.
United StatesIntellectual Property






